Welcome to our dedicated page for Twist Bioscience news (Ticker: TWST), a resource for investors and traders seeking the latest updates and insights on Twist Bioscience stock.
Twist Bioscience Corporation (NASDAQ: TWST) is a synthetic biology and biotechnology company whose news flow reflects its focus on synthetic DNA tools, silicon-based DNA synthesis and research-enabling technologies. Company announcements frequently describe Twist as a mid-cap growth and value biotech company serving customers in medicine, agriculture, industrial chemicals and defense, where its DNA-based products support research and development programs.
On this page, readers can follow TWST news related to product launches, collaborations, financial updates and corporate developments. Recent press releases have highlighted the launch of research-grade plasmid DNA preps for nucleic acid therapeutics research, including animal origin-free and transfection-grade options with specific quality attributes and target yields. Other announcements cover expanded collaborations, such as the Trinity Freestyle Fast Hybridization workflow developed with Element Biosciences for the AVITI sequencing platforms.
Investors and researchers can also track earnings-related news, including preliminary revenue updates, quarterly and full-year financial results, and associated conference calls and webcasts. Corporate governance and compensation updates, such as inducement equity grants under Nasdaq Listing Rule 5635(c)(4), appear in Twist’s news stream as well.
In addition, Twist publishes news on biosecurity and policy engagement, including participation in a Science paper examining biosecurity screening practices in AI-assisted protein design. Conference presentations at major healthcare and life science events are also regularly announced. For anyone following TWST stock or the evolution of synthetic DNA technologies, this news page provides a centralized view of Twist Bioscience’s public communications and key milestones.
Twist Bioscience (NASDAQ: TWST) has achieved LEED certification for its Wilsonville, OR facility, demonstrating its commitment to sustainability in operations and maintenance. The certification, awarded by the U.S. Green Building Council, recognizes the facility's adherence to LEED v4.1 Operations + Maintenance standards.
CEO Emily M. Leproust emphasized that this achievement aligns with Twist's mission to improve health and sustainability. The company previously quantified the carbon footprint of gene production using their platform, showing significant environmental benefits compared to traditional methods. This LEED certification further solidifies Twist's commitment to providing customers with DNA produced in a sustainable facility using fewer chemical reagents.
Twist Bioscience (NASDAQ: TWST) has released its 2024 corporate responsibility report, highlighting its commitment to sustainability, social responsibility, and ethics. The company's silicon-based DNA manufacturing platform offers a more sustainable alternative to legacy methods, using 99.8% less reagents than 96-well plate approaches.
Key points:
- Twist's oligo manufacturing process for NGS target enrichment panels emits significantly less CO2 compared to industry standards
- The company disclosed its Scope 1 and Scope 2 emissions for the first time
- Twist prioritizes biosecurity, cybersecurity, and data protection
- The company fosters a diverse workforce, with 56% of U.S. employees identifying as individuals of color
- Twist invested over $220,000 in employee learning and development in fiscal 2023
Twist Bioscience (NASDAQ: TWST), a leading synthetic DNA provider, has announced its participation in the Baird Global Healthcare Conference 2024. Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present on Tuesday, September 10 at 2:35 p.m. Eastern Time in New York City.
The presentation will be webcast live and accessible through the company's investor relations website. A replay will be available for 30 days following the event. This conference appearance provides an opportunity for Twist Bioscience to showcase its silicon-based DNA synthesis platform and engage with healthcare industry professionals and investors.
Twist Bioscience (NASDAQ: TWST) has expanded its DNA synthesis offering with the launch of Gene Fragments ranging from 1.8kb to 5.0kb in length. This industry-leading product is available through Twist's ecommerce platform, offering the same speed, quality, and affordability as shorter fragments. Key features include:
- Turnaround time starting at two business days
- Low error rate of 1:7,500 base pairs
- Customizable with no order limit
- Universally compatible with various downstream cloning methods
The expanded offering aims to serve researchers at all stages, from Makers to Buyers, and is particularly beneficial for RNA therapeutic screening applications. Twist's CEO, Emily M. Leproust, Ph.D., emphasized the company's goal to push the boundaries of DNA synthesis and meet diverse customer needs.
Twist Bioscience (NASDAQ: TWST) has announced the granting of 94,200 restricted stock units (RSUs) to 30 newly hired employees as an inducement for their employment. This action was taken under Twist's Inducement Equity Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over a 48-month period, with 25% vesting on the one-year anniversary of the employee's start date and 1/16 vesting quarterly thereafter, contingent on continued employment. This plan is exclusively used for granting equity awards to new hires or those returning after a significant break in employment.
Twist Bioscience (Nasdaq: TWST) and bitBiome have announced a strategic collaboration, launching a joint Transaminase Enzyme Screening Kit. This kit contains 48 diverse transaminase enzymes for in-house screening and evaluation. The collaboration combines Twist's high-capacity DNA synthesis technology with bitBiome's proprietary database of over two billion microbe sequences.
The kit aims to provide labs and pharmaceutical companies with improved enzymes for biocatalysis, particularly for synthesizing active pharmaceutical ingredients (APIs). Transaminases are important in creating chiral amines, valuable building blocks for the pharmaceutical industry, offering a potential 'green alternative' to conventional synthesis methods.
This partnership leverages bitBiome's diverse sequence database and Twist's large-scale DNA synthesis capabilities to create innovative solutions for the biomanufacturing industry.
Twist Bioscience (NASDAQ: TWST) reported strong fiscal Q3 2024 results, with record revenue of $81.5 million, up 28% year-over-year. The company saw significant improvements in gross margin, reaching 43.3%, a 900 basis point increase from the previous year. Twist raised its FY 2024 revenue guidance to $310-$311 million and expects gross margin to be at the high end of the range at approximately 42%.
Key highlights include:
- SynBio revenue grew to $33.0 million
- NGS revenue increased to $43.4 million
- Biopharma revenue reached $5.1 million
- Shipped products to approximately 2,300 customers
- Launched new products including Multiplexed Gene Fragments and Express Antibodies
Despite the strong revenue growth, Twist reported a net loss of $85.6 million for the quarter, including a $45 million impairment related to Biopharma assets.
Twist Bioscience (NASDAQ: TWST) announced the first patient dosing in Pure Biologics' exploratory Phase 0 clinical study of PBA-0405, a fully human IgG1 antibody discovered using Twist's synthetic antibody phage display libraries. The study aims to evaluate the pharmacodynamic activity of PBA-0405 in solid tumors, including head and neck squamous cell carcinoma, certain soft-tissue sarcomas, and triple-negative breast cancer.
PBA-0405 targets ROR1, a tumor-associated antigen, and is designed to make tumors visible to the immune system and induce an immune response. This marks the first antibody identified using Twist Biopharma Solutions' Library of Libraries to be tested in patients, validating the potential of their synthetic antibody libraries for discovering novel drug candidates for hard-to-treat cancers.
Twist Bioscience (NASDAQ: TWST) announced it will release its fiscal 2024 third quarter financial results on Friday, August 2, 2024, before market opening. The company will host a conference call and live audio webcast at 8:00 a.m. ET to discuss the results and provide business updates. The press release with financial results will be accessible on Twist Bioscience's website under the Investor Relations section. Interested participants can register on the company's website to receive the necessary dial-in information for the call. A webcast replay will be available for two weeks.
Twist Bioscience (NASDAQ: TWST) has expanded its high-throughput antibody portfolio with the launch of the CHO Express Antibodies, complementing their existing HEK293 antibodies. This expansion aims to support biopharma companies by providing customizable, cost-effective, and scalable antibody production solutions. CHO cell lines are pivotal in biotherapeutic drug manufacturing, and Twist's new service can deliver sequence-perfect IgG antibodies in as few as 13 business days. The antibodies range from 15 μg to 3,000 μg and include detailed yield data for screening. This development improves the efficiency and reduces the costs associated with antibody discovery and production.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
